Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bonus BioGroup Ltd. (BONS.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA (0.01 ILS)
Add to watchlist
35.60-1.70 (-4.56%)
At close: 05:24PM IDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close37.30
Open37.30
Bid35.60 x 100
Ask35.70 x 624100
Day's Range35.60 - 37.80
52 Week Range30.40 - 175.00
Volume2,785,859
Avg. Volume2,337,015
Market Cap41.064B
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    ‏Bonus BioGroup's COVID Drug - MesenCure - Can Help a Life-threatening Complication Seen in Cancer Patients

    Haifa-based Biotech company, Bonus BioGroup (TASE: BONS), has recently completed a preclinical trial demonstrating the efficacy of its drug MesenCure (developed for the treatment of severe COVID patients) in reducing life-threatening inflammatory overreaction, seen in patients with cytokine release syndrome (CRS).

  • GlobeNewswire

    POET Technologies to Report Full Year 2021 Financial Results on April 26

    Management to Host Business Update Conference Call on April 27TORONTO, April 21, 2022 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; Nasdaq: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today announced the Company will distribute its audited consolidated financial results for the fourth quarter and full year ended December 31, 2021 after the cl

  • Newsfile

    Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health

    Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, submitted results for its multicenter, Phase-II clinical trial to the Israeli Ministry of Health on January 9th. Following on the heels of the Company's initial release of encouraging preliminary results in November 2021, the trial data submitted last

Advertisement
Advertisement